BioSpace News Archive

First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent; First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Virtual Healthcare Conference.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.

Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances

– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth hormone deficiency diagnostic – – Planned safety and efficacy study AEZS-130-P02 (“Study P02”) of macimorelin expected to commence in Q4 2020 – – Advancing ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and other key global markets –

Digirad Corporation will release its financial results for the first quarter ended March 31, 2020, before the market opens on Friday, May 15, 2020.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020, which this year will be held digitally June 6-8, 2020. The study will be presented by Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Departme

Evofem Biosciences, Inc.today reported financial results for the three month period ended March 31, 2020.

Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional content of crops, today announced that it will release its financial and business results for the first quarter of 2020 after market close on May 13, 2020 .

Correvio Pharma Corp. (“Correvio” or the “Company”) (NASDAQ: CORV) (TSX: CORV), today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, released a report (the “Glass Lewis Report”) recommending that Correvio shareholders vote in favor of the proposed plan of arrangement